key: cord-1036376-9nvk2daw
authors: Carter, J. G.; Orueta Iturbe, L.; Duprey, J.-L. H. A.; Carter, I. R.; Southern, C. D.; Rana, M.; Bosworth, A.; Beggs, A. D.; Hicks, M. R.; Tucker, J. H. R.; Dafforn, T. R.
title: Sub-5-minute Detection of SARS-CoV-2 RNA using a Reverse Transcriptase-Free Exponential Amplification Reaction, RTF-EXPAR
date: 2021-01-04
journal: nan
DOI: 10.1101/2020.12.31.20248236
sha: 6f48e1b1ea7e4b2e98e654598648408be2fdd511
doc_id: 1036376
cord_uid: 9nvk2daw

We report a rapid isothermal method for detecting SARS-CoV-2, the virus responsible for COVID-19. The procedure uses a novel reverse transcriptase-free (RTF) approach for converting RNA into DNA, which triggers a rapid amplification using the Exponential Amplification Reaction (EXPAR). Deploying the RNA-to-DNA conversion and amplification stages of the RTF-EXPAR assay in a single step results in the detection of a sample of patient SARS-CoV-2 RNA in under 5 minutes.

imperative. A key part of this strategy is continuous assay development, with the aim of reducing 23 detection times and increasing sample throughput. The research community and diagnostics industry 24

has responded rapidly to this unprecedented crisis in developing a range of detection platforms. 1-4 25 The most sensitive assays detect viral RNA, with the current gold standard being reverse transcriptase 26 polymerase chain reaction (RT-PCR), a two-step assay that takes more than 60 minutes per sample. 27

First, reverse transcriptase converts viral RNA to complementary DNA (cDNA), a process that can 28 take up to 30 minutes. 5 Then a quantitative PCR (qPCR) amplifies the cDNA, which is detected using 29 a fluorescent dye, a process that takes up to an hour. 6 To reduce assay times, a plethora of new 30 approaches to SARS-CoV-2 detection have appeared in the literature over the past year. As far as 31

Nucleic Acid Amplification Tests (NAATs) are concerned, which are more sensitive than current 30-32 minute lateral flow antigen (immunoassay) tests, 7 focus has turned towards isothermal DNA 33 amplification approaches, which increase amplification speeds and hence reduce assay times. The 34 most common isothermal amplification system is Loop mediated isothermal AMPlification (LAMP). 8 35 LAMP assays have been developed for SARS-CoV-2 but take, on average, 20 minutes for a result, 36

with further decreases in LAMP assay time proving challenging. 4,9,10 Herein, we demonstrate an 37 alternative isothermal approach based on the Exponential Amplification Reaction (EXPAR), 11 a 38 simpler and faster amplification method than LAMP. By combining EXPAR with a novel reverse 39 transcriptase-free (RTF) step, this new assay, RTF-EXPAR, can accurately identify viral RNA 40 derived from COVID-19 patient samples in less than 5 minutes. 41 42

The key to the speed of EXPAR is twofold; firstly, the amplification occurs at a single temperature, 43 thus avoiding lengthy heating and cooling steps, and secondly the amplicon is relatively small 44 (typically 15-20 bases long), compared to both PCR and LAMP. These two factors result in EXPAR, 45 once triggered, producing up to 10 8 strands of DNA product in a matter of minutes. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 4, 2021. ; https://doi.org/10.1101/2020.12.31.20248236 doi: medRxiv preprint A crucial element to developing a successful EXPAR assay is the identification of optimal nucleotide 53 sequences in the target genome. Qian et al previously found that the type of trigger sequence used in 54 EXPAR plays a vital role in determining its efficiency. 13,14 Using their approach, we designed a 17-55 mer DNA trigger for EXPAR (Trigger X, Scheme 1a and Table 1 ) containing a sequence 56 complementary to one within the conserved gene Orf1ab in the SARS-CoV-2 genome 57 (https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3?report=fasta). We first analysed the speed and 58 sensitivity of EXPAR using Trigger X in the presence of Template X´-X´ (Supplementary Figure  59 1). Rapid rises in SYBR Green fluorescence were observed, with amplification times revealing an 60 expected dependence on trigger concentration (e.g. time to 10-sigma: 3.17 ± 0.14 minutes at 10 nM, 61

8.67 ± 1.08 minutes at 10 pM). These results demonstrate that EXPAR is a faster amplification 62 method than LAMP. Next, we analysed the specificity of the reaction by investigating three other 63 triggers (Triggers A, B and C), each at a concentration of 10 nM, that were non-complementary to 64

Template X´-X´ (Supplementary Figure 2) . Each of these three triggers produced no signal within 65

10 minutes under the same conditions, confirming the specificity of the EXPAR reaction, with only 66 the trigger sequence fully complementary to the template (Trigger X) resulting in rapid amplification. 67 68

In the standard RT-PCR COVID-19 assay, reverse transcriptase converts the RNA of SARS-CoV-2 69

into cDNA prior to amplification (vide supra). Applying this novel EXPAR approach in a two-stage process, we first undertook an enzymatic 87 digestion at 50 °C for five minutes of Binder DNA (1 µM) in the presence of a sample of patient 88 SARS-CoV-2 RNA (72.7 copies/µL) 16 obtained from PHE, before adding this solution to the EXPAR 89 reagent mix for the amplification step. This stage, performed in triplicate, gave an amplification time 90 of 3.17 ± 0.24 minutes, whereas no amplification was observed for the negative sample within 10 91 minutes ( Fig. 1 and Supplementary Figure 3) . To increase the speed of the RTF-EXPAR assay further, 92 we next investigated a "one-pot" approach by introducing BstNI and Binder DNA to the EXPAR 93 reagents at the same time, before incubating and amplifying simultaneously at 50 °C. These assay 94

conditions gave an amplification time of only 4.00 ± 0.72 minutes for the positive sample, halving 95 the total assay time compared to the "two-pot" method ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 4, 2021. ; https://doi.org/10.1101/2020.12.31.20248236 doi: medRxiv preprint successful detection of SARS-CoV-2 RNA in a total assay time of less than 5 minutes. This time is 105 not only much faster than RT-PCR (assay time of at least 60 minutes) but also outperforms LAMP 106

and 30-minute lateral flow antigen tests in current deployment. RTF-EXPAR would be completely 107 compatible (i.e. deployment ready) for use on equipment currently used for RT-PCR COVID-19 108 assays. Furthermore, the simplicity and speed of the assay enables this method to be modified to 109 detect a range of infectious diseases caused by RNA-based pathogens (e.g. Ebola, RSV is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 4, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 4, 2021. Author is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 4, 2021. (2) Specificity test (no RNA target): 3 µL of one trigger at 100 nM (Trigger X or Trigger A or 240

Trigger B or Trigger C) 241 OR 242

(3) Reverse Transcriptase-Free EXPAR assay (two-pot RTF-EXPAR): 10 µL of RNA:DNA 243

heteroduplex digestion mixture, prepared as follows: 25 µL of water, 5 µL of 10x Isothermal 244 amplification buffer, 5 µL BstNI (10 U/µL), 10 µL of Binder DNA (1 µM) and 5 µL of viral sample. 245

The mixture is then incubated at 50 °C for 5 minutes. 246 OR 247

(4) Reverse Transcriptase-Free EXPAR assay (one-pot RTF-EXPAR): reagents are mixed together 248 in the following order: 1 µL BstNI (10 U/µL), 2 µL of Binder DNA (1 µM) and 3 µL of viral sample. 249 250

Addition step: Part B (17 µL) is added to a PCR tube, and to this is added Part C, followed by 251

Part A (10 µL). The tube is then sealed, with the contents then subjected to amplification. 252 253

Amplification step: Isothermal incubation and fluorescence signal measurements are performed using 254

an Agilent Mx3005P Real-Time PCR system (Didcot, UK) set to a constant temperature of 50 °C. 255

The fluorescence is measured every 10 seconds over an incubation time of 30 minutes. 256 257 258

References 259

The explosion of new coronavirus tests that could help to end the pandemic

Towards effective diagnostic assays for COVID-19: a review

Coronavirus and the race to distribute reliable diagnostics

Assay techniques and test development for COVID-19 Diagnosis

The use of real-time reverse transcriptase PCR for the quantification of 268 cytokine gene expression

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT

Covid-19: Innova lateral flow test is not fit for "test and release" strategy, say 272 experts

Loop-mediated isothermal amplification of DNA

SARS-CoV-2 detection using isothermal amplification and a rapid, 276 inexpensive protocol for sample inactivation and purification

Rapid isothermal amplification and portable detection system for SARS-CoV-279 2

Isothermal reactions for the amplification of 281 oligonucleotides

Exponential Isothermal Amplification of Nucleic Acids 283 and Assays for Proteins, Cells, Small Molecules, and Enzyme Activities: An EXPAR Example

Sequence dependence of isothermal DNA amplification via EXPAR

Reduction of Background Generated 288 from Template-Template Hybridizations in the Exponential Amplification Reaction

Sequence-specific cleavage of RNA by Type II 291 restriction enzymes

The average viral load in respiratory samples has been reported to be 10 5.85 copies/mL, which 293 equates to ca. 700 copies/µL; see: Kleiboeker, S. et al. SARS-CoV-2 viral load assessment in 294 respiratory samples